FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for IV Push

SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news